Medtronic Ardian Luxembourg S.a.r.l.

May Health US Inc.

Medtronic Ireland Manufacturing Unlimited Company

Ablacare, Inc.

Concentric Medical, Inc.

Ziva Medical, Inc.

Neil Chand Barman

Denise Marie Zarins

Garrett Marc Schwab

Douglas Sutton

Roger Osborne

Mark Gelfand

Andrew H Wu

Howard Levin

Dwayne S Yamasaki

Paul A Sobotka

Benjamin J Clark

Maria G Aboytes

Carol M Sullivan

Robert J Beetel

Paul Sobotka

John Miller

Scott D Wilson

Ron French

Ayala Hezi-Yamit

Emily Vu

Stefan Stoyanov Tunev

Carol Sullivan

Andrew Wu

Catheter-based devices and associated methods for immune system neuromodulation of human patients are disclosed herein. One aspect of the present technology is directed to methods of treating a human patient diagnosed with an immune system condition. The methods can include intravascularly positioning a neuromodulation catheter within a blood vessel proximate to neural fibers innervating an immune system organ of the patient. The method also includes reducing sympathetic neural activity in the patient by delivering energy to the neural fibers innervating the immune system organ via the neuromodulation catheter. Reducing sympathetic neural activity improves a measurable physiological parameter corresponding to the immune system condition of the patient.

Catheter-based devices and associated methods for immune system neuromodulation

Described here are methods and systems for the manipulation of ovarian tissues. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The systems and methods may be useful in the treatment of infertility associated with PCOS.

Methods and systems for the treatment of polycystic ovary syndrome

Methods for treating and managing pain in a patient with therapeutic neuromodulation and associated systems and methods are disclosed herein. Chronic or debilitating pain can be associated, for example, with a disease or condition of the abdominal or reproductive viscera. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a target blood vessel of a diseased or damaged organ of a patient experiencing pain. Targeted sympathetic nerve activity can be modulated at least along afferent pathways which can improve a measurable parameter associated with the pain of the patient The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

Neuromodulation and associated systems and methods for the management of pain

Described here are methods and systems for the manipulation of ovarian tissues. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The systems and methods may also be useful in the treatment of infertility associated with PCOS.

Methods and systems for the manipulation of ovarian tissues

Catheter assemblies for neuromodulation proximate a renal artery bifurcation and associated systems and methods are disclosed herein. A catheter assembly configured in accordance with a particular embodiment of the present technology can include a shaft having a proximal portion, a distal portion, and two therapeutic arms extending from the distal portion. The shaft can be configured to deliver the distal portion to a treatment site proximate a branch point or bifurcation in a renal blood vessel. The therapeutic arms can include energy delivery elements that are configured to deliver the therapeutically-effective energy to renal nerves proximate the branch point.

Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods

Methods for treating gastrointestinal conditions, conditions associated with sympathetic and/or parasympathetic activity in the gastrointestinal organs, and conditions associated with central sympathetic and/or parasympathetic activity in a patient with therapeutic gastrointestinalneuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a gastrointestinal artery of a gastrointestinal organ of a patient. Sympathetic drive in the patient can thereby be reduced in a manner that treats the patient for the gastrointestinal condition.

Gastrointestinal neuromodulation and associated systems and methods

Growing community of inventors

Menlo Park, CA, United States of America

Neil Chand Barman